CMOP±R in the Treatment of Untreated Non-Hodgkin's Lymphoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

197

Participants

Timeline

Start Date

July 10, 2024

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2027

Conditions
NHL
Interventions
DRUG

CMOP±R

Drug: Mitoxantrone hydrochloride liposome Mitoxantrone hydrochloride liposome (18 mg/m\^2) on day 1, every 4 weeks; Drug: Cyclophosphamide Cyclophosphamide(750 mg/m\^2) on day 1, every 4 weeks; Drug: Vincristine Vincristine (1.4mg/ m2,Max dose 2mg) will be administered on day 1(Or at the discretion of the investigator, use other vinblastine drugs with the same mechanism, such as vindesine 2-3 mg/m2 on day 1), every 4 weeks; Drug: Prednisone Prednisone (100 mg) will be taken orally from day 1-5(Or equivalent dose of dexamethasone at 15mg), every 4 weeks; Drug: Rituximab Rituximab (375mg/m\^2) on day 0, every 4 weeks, only with CD20-positive lymphomas are evaluated by the investigator.

All Listed Sponsors
lead

The First Affiliated Hospital of Soochow University

OTHER